Trading Update

Dec 17, 2009

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 2612E
Advanced Medical Solutions Grp PLC
17 December 2009
 



For  Immediate Release

  17 December 2009

Advanced Medical Solutions Group plc 

(“AMS” or “the Company”)

Trading Update

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces an update on trading prior to its close period for the year ending 31 December 2009. 

Dr. Geoffrey Vernon, Chairman of Advanced Medical Solutions Group plc, stated:

“I am pleased to report that AMS has had a strong second half of the year and that the Board expects full year earnings to be in line with market expectations.  

“The Company has commenced sales of its LiquiBand™ topical skin adhesive products in the US market. Whilst FDA approval is still under review for LiquiBand™ products with specific applications in the operating room, current budgets are covered by the products already approved.

“Integration of the Corpura business acquired in October 2009 is proceeding well and is confirming our belief that polyurethane foam will be one of the key drivers of future growth for the Company.

“The new facility at Winsford is also proceeding well. Phase I fit–out covering the warehouse, laboratories, offices and initial manufacturing clean rooms is complete.  Equipment is being installed and regulatory approval has been received from BSI, our notified body, which now allows us to ship product from the new site. Phase II fit–out covering the remainder of the manufacturing clean rooms is well underway, and the entire project remains within budget and on track for completion by the end of 2010 as planned. It will provide AMS with a world class medical device facility to support its future growth plans.“

-ENDS- 

For further information, please contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

www.admedsol.com

  Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Gary Clarence / Tim Pratelli / Daniel Adams

Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its in-house technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TSTILFVDFFLRLIA

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.